Cargando…

Effective treatment of severe acute pancreatitis and COVID-19 pneumonia with tocilizumab

Detalles Bibliográficos
Autores principales:	Zielecki, Piotr, Kaniewska, Magdalena, Furmanek, Mariusz, Bulski, Tomasz, Rydzewska, Grażyna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509907/ https://www.ncbi.nlm.nih.gov/pubmed/33005274 http://dx.doi.org/10.5114/pg.2020.99042

Ejemplares similares

Gastrointestinal symptoms in COVID-19
por: Lewandowski, Konrad, et al.
Publicado: (2022)

The Use of Virtual Reality to Reduce Stress among Inflammatory Bowel Disease Patients Treated with Vedolizumab
por: Lewandowski, Konrad, et al.
Publicado: (2021)

High-flow nasal oxygen in severe COVID-19 pneumonia and tocilizumab
por: Mandal, M., et al.
Publicado: (2022)

Biosimilar infliximab versus originator in Crohn’s disease anti-TNF-α naïve and non-naïve patients
por: Kaniewska, Magdalena, et al.
Publicado: (2020)

Tocilizumab in severe COVID-19
por: Lucio Liberato, Nicola, et al.
Publicado: (2020)

Gastrointestinal symptoms in patients with coronavirus disease 2019 (COVID-19) – friend or foe?
por: Lewandowski, Konrad, et al.
Publicado: (2021)

Statistical models to predict clinical outcomes with anakinra vs. tocilizumab treatments for severe pneumonia in COVID19 patients
por: Piconi, Stefania, et al.
Publicado: (2023)

Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia
por: Aomar-Millán, Ismael F., et al.
Publicado: (2022)

The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome
por: Lewandowski, Konrad, et al.
Publicado: (2022)

The efficacy and safety of the biosimilar product (Inflectra(®)) compared to the reference drug (Remicade(®)) in rescue therapy in adult patients with ulcerative colitis
por: Kaniewska, Magdalena, et al.
Publicado: (2017)

Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Fioravanti, Antonella, et al.
Publicado: (2020)

Skin and gastrointestinal symptoms in COVID-19
por: Ciechanowicz, Piotr, et al.
Publicado: (2020)

Authors’ Reply to: Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Liu, Bin, et al.
Publicado: (2020)

Biosimilar biological drugs in the treatment of inflammatory bowel diseases
por: Kaniewska, Magdalena, et al.
Publicado: (2019)

Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia
por: Gokhale, Yojana, et al.
Publicado: (2020)

Immature granulocytes predict severe acute pancreatitis independently of systemic inflammatory response syndrome
por: Lipiński, Michał, et al.
Publicado: (2017)

Selected Aspects of Nutrition in the Prevention and Treatment of Inflammatory Bowel Disease
por: Panufnik, Paulina, et al.
Publicado: (2022)

Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia
por: Chauvineau-Grenier, Angélique, et al.
Publicado: (2022)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment
por: Yurttutan, Sadık, et al.
Publicado: (2021)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Use of tocilizumab in multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2
por: Banday, Aaqib Zaffar, et al.
Publicado: (2021)

Tocilizumab in a Child with Acute Leukoencephalopathy with Restricted Diffusion
por: Jaiswal, Anshul, et al.
Publicado: (2023)

Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment()
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2023)

Low-FODMAP Diet for the Management of Irritable Bowel Syndrome in Remission of IBD
por: Więcek, Martyna, et al.
Publicado: (2022)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Successful treatment of an enterovesical fistula due to Crohn’s disease with stem cell transplantation: a case report
por: Moniuszko, Andrzej, et al.
Publicado: (2018)

Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19
por: Foo, Hong, et al.
Publicado: (2023)

Long-lasting dyspeptic symptoms – another consequence of the COVID-19 pandemic?
por: Nazarewska, Anna, et al.
Publicado: (2023)

Tocilizumab-induced granulomatous vasculitis and cutaneous actinomycosis in a patient with rheumatoid arthritis
por: Ziandarska, Justyna, et al.
Publicado: (2022)

Applying Hot Compresses with Rhubarb and Mirabilite to Reduce Pancreatic Leakage Occurrence in the Treatment of Severe Acute Pancreatitis
por: WANG, Yunxia, et al.
Publicado: (2017)

The introduction of the IBD Disk in Poland – a new tool for assessing disability in patients with inflammatory bowel disease
por: Eder, Piotr, et al.
Publicado: (2019)

Prediction of moderately severe and severe acute pancreatitis in pregnancy: Several issues
por: Yang, Qun-Ying, et al.
Publicado: (2022)

Tocilizumab administration in a refractory case of COVID-19
por: Dastan, Farzaneh, et al.
Publicado: (2020)

Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?
por: Gupta, Rahul
Publicado: (2022)

Efficacy of tocilizumab treatment in severely ill COVID-19 patients
por: Zhao, Jie, et al.
Publicado: (2020)

Cytomegalovirus Viremia, Pneumonitis, and Tocilizumab Therapy
por: van Duin, David, et al.
Publicado: (2011)

Effectiveness of Crohn’s Disease Exclusion Diet for Induction of Remission in Crohn’s Disease Adult Patients
por: Szczubełek, Martyna, et al.
Publicado: (2021)

Reply to van Lingen et al. Comment on “Szczubełek et al. Effectiveness of Crohn’s Disease Exclusion Diet for Induction of Remission in Crohn’s Disease Adult Patients. Nutrients 2021, 13, 4112”
por: Szczubełek, Martyna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_efqc38vpvd6019qiggkmvoitvu